Lupin Launches World's First Triple-Combination Inhaler for COPD

• Product: Formoflo-G MDI (Glycopyrronium, Formoterol, and Fluticasone).
• Market: India's respiratory segment, targeting 55 million COPD patients.

Reader Takeaway: Lupin adds a world-first therapy to its portfolio, potentially strengthening its #2 market position in respiratory care.

What just happened

Lupin Limited has officially launched Formoflo-G MDI, a fixed-dose triple-combination inhaler, following approval from the Drug Controller General of India (DCGI). The medication is designed for the long-term management of moderate to severe chronic obstructive pulmonary disease (COPD) and is administered twice daily.

Why this matters

This launch marks a significant milestone as the world’s first triple-combination metered-dose inhaler for COPD. By addressing a major chronic condition affecting 55 million people in India, the product serves as a key pillar in Lupin’s specialty medicine strategy. For shareholders, this signals a focus on complex generics that can differentiate the company in a crowded pharmaceutical market.

What changes now

Lupin intends to use this launch to bolster its existing respiratory portfolio. As the #2 player in this therapeutic segment according to IQVIA data (MAT March 2026), the company is positioning itself to gain further market share by offering healthcare professionals a high-quality, comprehensive treatment option.

Risks to watch

Investors should monitor the commercial uptake and adoption rates of Formoflo-G among pulmonologists and general practitioners. As with any new pharmaceutical launch, the impact on earnings will be determined by the speed of market penetration and competitive pricing strategies in the respiratory space.

What to track next

Watch for upcoming earnings reports for commentary on the product's initial sales trajectory and any further expansion plans for the India Region Formulations division.